Prime Editing and CRISPR Market Size, Share, Industry, Forecast and outlook (2024-2031)

Prime Editing and CRISPR Market is segmented By Service (Cell Line Engineering, Genome Regulation, Gene Editing, Gene-Modified Cell Therapy), By Application (Biomedical Research & Therapy, Agricultural Research, Others), By End-User (Academic Institutes, Biotechnology & Pharma Companies, Contract Research Organizations, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis,  2024-2031.

 Prime Editing and CRISPR  Market is estimated to grow at a CAGR of 24.1% during the forecast period (2024-2031). 179 pages report analyses the Prime Editing and CRISPR market shares, recent trends, competitive intelligence and future market outlook. Prime Editing and CRISPR usage ingenome editing techniques is on the rise. Competitive rivalry intensifies with  GenScript Biotech, Horizon Discovery, Integrated DNA Technologies and others operating in the market

Prime editing and CRISPR are genome editing techniques that use a search and replace technique to modify the genome of a living creature. Engineered prime editing guide RNA (pre RNA) and a prime editor are the two components of prime editing (PE). It comprises a variety of genetic engineering tools and strategies for modifying a specific DNA sequence.

Prime Editing and CRISPR Market Scope

For know more Insights - Download Sample

Prime Editing and CRISPR Market Dynamics

The global prime editing and CRISPR market is growing due to advances in genetic engineering research and development, rising demand for genetically modified crops, and an increase in the occurrence of chronic and genetic disorders.

Growth in R&D in genetic engineering will drive the market growth   

Recent advances in genomic high-throughput platforms for DNA in genetic engineering and regulatory analysis have paved the path for novel therapeutic medicines. Because of technological improvements, scientists have created new and more effective genome editing techniques, including prime editing and CRISPR technology. Researchers at the Medical College of Georgia in the United States, for example, revealed in March 2021 that prime editing technology had enlarged the genetic toolbox for producing illness animal models and repairing genetic issues. Furthermore, according to the American Association for the Advancement of Science (AAAS), Jennifer Doudna employed CRISPR gene-editing technology to identify the coronavirus in under 5 minutes in 2020.

Moreover, the global prime editing and CRISPR market is primarily driven by an alarming rise in the prevalence of genomic and chronic diseases such as sickle cell anemia, cystic fibrosis, and lung cancer; increased government funding for genomic projects; increased demand for genetically mutated crops; advances in gene R&D; and increased awareness about genetic engineering. For example, the World Health Organization (WHO) estimates that around 10 million people will die from cancer in 2020. According to the Cystic Fibrosis Foundation (Cff) data, 70,000 people worldwide were diagnosed with cystic fibrosis in 2019, with more than 1000 new cases reported each year. Furthermore, the market is expected to develop due to an increase in demand for genetic engineering in biomedical research and the requirement for gene editing. As a result, the market is predicted to develop due to an increase in the frequency of genetic-based diseases and a surge in demand for gene manipulation.

The expansion of the global prime editing and CRISPR market is being driven by a boost in funding from corporate and government organizations for genomic projects and an increase in the use of genetically altered crops. Furthermore, because gene insertion and deletion techniques are utilized to treat numerous chronic diseases, the rise in occurrences of diseases such as cancer adds considerably to market growth. An increase in genomic research efforts is driving the global market. Furthermore, governments support regenerative medical research through various initiatives projected to enhance the market growth. In addition, SingHealth Duke-NUS Academic Medical Centre will introduce sophisticated regenerative medicine and cellular therapy in 2021 to improve patient care. The study's goal is to investigate regenerative cell therapy as a treatment for blood malignancies, heart failure, and vision loss. On the contrary, advances in R&D for genetic engineering technology in emerging countries are expected to open up attractive business potential. For example, in 2021, scientists at UC Berkeley in San Francisco conducted the first clinical trial of CRISPR gene repair treatment in sickle cell disease patients.

Ethical and legal issuesis likely to hamper the market growth 

Many parts of gene editing are fraught with ethical concerns. Most ethical concerns are with genome editing centers in the human germline. Gene editing in the human germline has been passed down from generation to generation. Furthermore, the National Human Genome Research Institute (NIH) in Maryland does not sponsor a project involving human embryo gene editing. Furthermore, the family's informed consent and ownership must be obtained due to legal and ethical concerns. As a result, all of these constraints, taken together, limit market expansion.

COVID-19 Impact Analysis

The global prime editing and CRISPR markets are expected to develop due to the COVID-19 epidemic. The COVID-19 pandemic has put a strain on the global healthcare system, highlighting the need for a vaccine and monoclonal antibodies to prevent and cure people infected with the coronavirus. The DNA and RNA of the coronavirus have been studied extensively to determine how it infects human cells and how it causes disease.

The COVID-19 vaccine might be made in months rather than years. Researchers at the Medical College of Georgia in the United States, for example, created a primary editing technique in March 2021, which effectively changed genes in mice and enlarged the genetic toolbox for producing disease models. Furthermore, scientists at Stanford University in California launched the PAC-MAN tool in June 2020. In human cells, this genetic editing technology targets and eliminates certain genetic strands of the virus. As a result, numerous biotechnology and pharmaceutical businesses, universities, and laboratories are seeing a surge in demand for gene editing.

Prime Editing and CRISPR Segment Analysis

The gene editing segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)        

The global primary editing and CRISPR market is divided into four categories based on service: cell line engineering, gene editing, genome regulation, and gene-modified cell therapy. In 2023, the gene-editing segment will dominate the market due to a growth in demand for gene editing in the targeted drug development process and advancements in genomic disease research. Gene editing, also known as genome editing, is deleting, inserting, replacing, or modifying DNA in living organisms' genomes. It's a sort of genetic engineering in which a set of technologies and scientists alter an organism's DNA like bacteria, plants, or mammals. Editing DNA results in physical characteristics such as illness risk and eye color changes.

The market's growth is fueled by an increase in the frequency of chronic diseases, a surge in demand for regenerative medicine, breakthroughs in genome editing technologies, and R&D. In 2020, the gene-editing sector dominated the market and this trend is likely to continue over the forecast period. This is due to the rising demand for gene editing in the targeted drug discovery process and advances in genomic illness research.

Prime Editing and CRISPR Market Geographical Analysis

Asia-Pacific region holds the largest market share of the global prime editing and CRISPR market

Asia-Pacific is anticipated to dominate the prime editing and CRISPR market, globally. The market's expansion is fueled by an increase in the prevalence of chronic diseases, an increase in the geriatric population, an increase in demand for novel medications in India, China, and Japan, and an increase in research laboratories. According to the United Nations Population Fund (UNFPA), the Asia-Pacific geriatric population will triple by 2050, reaching 1.3 billion people. Because of diminished genetic stability and less immune cell activity, the geriatric population is more likely to suffer chronic disease, which supports regional expansion. The World Health Organization (WHO) estimated that 1,028,658 people were diagnosed with cancer in Japan in 2020.

Additionally, the global demand for gene editing products is likely to provide lucrative prospects for market expansion. New research and insights are used to build gene modification applications. Congenital blindness, sickle cell anaemia, lung tumours, and cystic fibrosis are just a few of the chronic and hereditary disorders for which human genetic engineering holds a lot of promise. For example, one of the biggest pharmaceutical companies, Novartis, announced CAR-T cell therapy to treat patients with blood cancer in 2021. CAR-T treatment is a cutting-edge immunotherapy that alters the T cells of patients to recognise and kill malignant cells.

Prime Editing and CRISPR Market Competitive Landscape

The prime editing and CRISPR market is a highly competitive presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Beam Therapeutics, GenScript Biotech, Horizon Discovery, Integrated DNA Technologies, Inscripta, Precision Bioscience, ThermoFisher Scientific Inc, Lonza among others.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the prime editing and CRISPR market globally. For instance,

• In June 2020, Magenta Therapeutics and Beam Therapeutics have announced non-exclusive research and clinical collaboration agreement to assess the potential utility of MGTA-117, Magenta's novel targeted ADC, for conditioning sickle cell disease and beta-thalassemia patients receiving Beam's base editing therapies.
• In June 2021, CRISPR Therapeutics and Capsida have formed a strategic partnership to research gene-edited therapeutics for Friedreich's ataxia and Amyotrophic lateral sclerosis, respectively.

Precision Bioscience

Overview:

Precision BioSciences, Inc., a genome editing company based in the United States, creates therapeutic products. The company is divided into two divisions: therapeutic and food. It provides ARCUS, a genome editing platform for treating genetic disorders.

Product Portfolio:

ARCUS:  Precision BioSciences scientists developed ARCUS, a proprietary genome editing technology. Several allogeneic, "off-the-shelf" CAR T immunotherapies are currently in early-stage clinical trials, with other in vivo gene editing programs in late-stage preclinical development.ARCUS is based on the I-CreI enzyme, which evolved in the algae Chlamydomonas reinhardtii to make highly specific cuts and DNA insertions in cellular DNA. I-CreI belongs to a larger class of enzymes known as homing endonucleases or meganucleases.